Osteoporosis, bone & mineral

Pre-teriparatide anti-osteoporosis medication therapy and fracture-related hospitalization in patients at very high fracture risk

Osteoporos IntPublished Retrospective cohort study

Main finding · Fracture-related hospitalizationResult — go to the resultHazard ratio 0.92 95% CI 0.83–1.02

Authors' conclusion

Prior AOM therapy was not associated with an increased fracture-related hospitalization risk after starting teriparatide in patients at very high fracture risk. However, among those who used AOM before teriparatide initiation, long-term denosumab use (≥ 3 years) was associated with an increased risk of spine fracture-related hospitalization.

Study context

Population
Patients at very high fracture risk initiating teriparatide, Taiwan
Participants
14,770 patients
Exposure
Prior anti-osteoporosis medication (AOM) use vs no prior AOM use before teriparatide initiation
  • AOMn = 9,127
  • Non-AOMn = 5,643reference
Outcome
Hospitalization for major osteoporotic fractures
Follow-up
Within 3 years
Methodological detailsnationwide, Taiwan National Health Insurance Research Database (2013-2019)
  • Nationwide
  • Taiwan National Health Insurance Research Database (2013-2019)

Main finding

Fracture-related hospitalization

Hazard ratio

0.92

95% CI 0.83–1.02

P = 0.102

AOMvs Non-AOM
HR 0.92 (95% CI 0.83–1.02); P = 0.102

As reported in the abstract

Observational data: associations, not effects.

Further findings

OutcomeHR (CI)P value
Spinal fracture-related hospitalization0.85 (0.73–0.98)P = 0.026

Fracture-related hospitalization, prior bisphosphonate

HR (95% CI)
Bisphosphonate0.85 (0.75–0.96)

Spinal fracture-related hospitalization, prior bisphosphonate

HR (95% CI)
Bisphosphonate0.83 (0.76–0.91)
OutcomeaHRP value
Spine fracture-related hospitalization, denosumab ≥ 3 vs < 3 years1.86P = 0.011
Spine fracture-related hospitalization, denosumab ≥ 3 vs < 3 years · first 6 months of transitioning1.98P = 0.031

Fracture and spinal fracture-related hospitalization, prior denosumab

Decreased risk not shown in denosumab users

Original publication

Pre-teriparatide anti-osteoporosis medication therapy and fracture-related hospitalization in patients at very high fracture risk. Osteoporos Int. Published 2 June 2026. doi:10.1007/s00198-026-08081-8

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.